Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : GSLI Lumonics -- Ignore unavailable to you. Want to Upgrade?

To: john p. carney who wrote (293)	8/21/2000 9:30:15 AM
From: Ram Seetharaman	Read Replies (1) \| Respond to of 328

They sure are getting rid of businesses that don't grow in line with their model! $ 120 million from this one - looking good - this GSLI, I tell you! Monday August 21, 8:41 am Eastern Time Press Release SOURCE: GSI Lumonics Inc. GSI Lumonics Announces Sale Of Its Life Sciences Business To Packard Bioscience Company KANATA, Ontario, Aug. 21 /CNW/ -- GSI Lumonics Inc. (Nasdaq: GSLI and TSE: LSI) today announced the sale of its Life Sciences business to Packard BioScience Company (Nasdaq: PBSC - news). Under the terms of the transaction, which is expected to close by the end of the third quarter following applicable regulatory approvals, Packard BioScience will acquire the operating assets related to the business from GSI Lumonics for a combination of cash and stock currently valued at approximately $120 million (US). GSI Lumonics' Life Sciences products are software controlled confocal scanning systems for the analysis of fluorescently labeled microarray biochips under the ScanArray® and QuantArray® tradenames. Applications include gene expression, genotyping, mapping, high-throughput screening and drug discovery. Life Sciences represents approximately 5% of total GSLI sales and 75 of approximately 1,400 employees. "We are pleased to have Packard BioScience as a strategic buyer for our life sciences business," said Charles Winston, President & CEO of GSI Lumonics. "By combining our technology and talented employees with Packard's worldwide distribution network, Packard will continue to rapidly grow the business. This is clearly a win-win relationship where the true beneficiaries will be the customers and employees of both companies. This sale is consistent with our previously announced strategy to focus our resources to providing laser systems and components to meet the growing demands in our core markets of semiconductor, electronics, automotive and, more recently, precision optics for telecommunications." "The acquisition of GSI Life Sciences will position Packard among the top three global providers of biochip and microarray tools for genomic and proteomic analysis. GSLI's instruments and software products will be a key feature of our product offering to the life science market," said Emery Olcott, Chairman & CEO of Packard BioScience Company. "Meeting the needs of existing GSI Lumonics customers is a top priority and we are committed to providing the highest level of service and best available products to these customers." Packard BioScience Company located in Meriden, Connecticut, is a leading global developer, manufacturer and marketer of instruments and related consumables and services for use in the life sciences research and nuclear industries. GSI Lumonics Inc. supplies laser-based automated advanced manufacturing systems, components and services to semiconductor, electronics and automotive markets and provides precision optics for telecommunications. GSI Lumonics' common shares are listed on Nasdaq (GSLI) and The Toronto Stock Exchange (LSI). The Company's web site address is www.gsilumonics.com. For more information: Fran Crecco GSI Lumonics Inc. 978-439-5511 (ext: 6104) To the extent this new release discusses financial projections, information or expectations about GSI Lumonics Inc., products or markets, or otherwise makes statements about the future, such statements are forward looking and are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. The factors include the fact that the Company's sales have been and are expected to continue to be dependent upon customer capital equipment expenditures, which are, in turn, affected by business cycles in the markets served by those customers. Other factors include volatility in the semiconductor industry, the risk of order delays and cancellations, the risk of delays by customers in introducing their new products and market acceptance of products incorporating subsystems supplied by the Company, similar risks to the Company of delays in its new products and other risks detailed in the Company's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. /Company News On-Call: prnewswire.com or fax, 800-758-5804, ext. 107189/ For further information Fran Crecco of GSI Lumonics Inc., 978-439-5511 (ext: 6104)

To: john p. carney who wrote (293)	9/27/2000 9:50:31 PM
From: BMcV	Read Replies (1) \| Respond to of 328

Well, John Looks like I screwed up again. Tried to buy a one-way ticket and it looks like I got stuck with a round-tripper! It seems GSLI is firmly in the semi-equip universe, not the exalted ether of FO. Our comparables are ASYT, BRKS, PRIA, ESIO; not JSDU, CIEN, even--god forbid!--RDRT. ESIO reports 83 cents, better than GSLI's total estimated 200 earnings!, and the stock trades at 35. So maybe we should feel too bad. When this insanity is over, we should be ok. I've been waiting for funds to start their quarter-end buying bash all week--if it doesn't start tomorrow in a big way, it looks like it won't happen at all. But really, the reason I'm writing this is to see what your feelings are about ADCT. {I'll excuse that flood of vomit} At 25 1/2, shouldn't we be buying the damn thing? I have a bunch of shares of Keybank that I'm thinking of trading one for one tomorrow morning. But I haven't been following ADCT as closely as I might have been, had I not simply given the new guys the benefit of the doubt--that is, once the PAIR antics were over, it seemed safe to let this one ride. Have you been watching? Is there really something going on besides the usual games being played?